XNZE
CVT
Market cap24mUSD
Nov 13, Last price
0.60NZD
Name
Comvita Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Comvita Limited, along with its associated entities, specializes in the global production and distribution of natural health products. The company boasts a significant international presence, operating across diverse markets in Australasia, Asia (including China), North America, Europe, the Middle East, and Africa. Its extensive product portfolio features flagship items such as Manuka honey, propolis, and olive leaf extract. Additionally, it offers a wide array of medihoney, skincare, gourmet honey, elixirs, lozenges, and cider vinegar formulations, as well as dedicated solutions for oral and children's health. Comvita's range is meticulously designed to address diverse wellness needs, including supporting digestive health, soothing eczema-prone skin, boosting energy levels, promoting cardiovascular well-being, and fortifying immune support. The company also provides essential solutions for summer and travel requirements. Beyond product development, Comvita maintains a vertically integrated operational model, encompassing the ownership and management of apiaries (beekeeping operations), property assets, and valuable intellectual property. Established in 1974, Comvita Limited is headquartered in Te Puke, New Zealand.
Key people
Karl Gradon
Chief Executive Officer · since 2025
Brett Hewlett
Acting Chief Executive Officer · since 2024
Nigel Greenwood
Chief Financial Officer · since 2020
Mandy Tomkins-Dancey
Chief Financial Officer · since 2025
Ben Duncan
Interim Chief Operating Officer · since 2025
Monica Yianakis
Chief Digital and Marketing Officer · since 2024
Jackie Evans
Chief Science Officer · since 2020
Maria Cowdrey
Executive Assistant · since 2025
Nikki Leske
Head of People and Technology · since 2025
Erin Swanson
Head of Sustainability and Strategic Projects · since 2025
Wu Yawen
Non-Executive Director · since 2021
Bridget Coates
Independent Non-Executive Chairman of the Board · since 2024
Lucas Bunt
Non-Executive Independent Director · since 2024
Robert Major
Non-Executive Independent Director · since 2019
Michael Sang
Non-Executive Independent Director · since 2023
Valuation
Title NZD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||